| Tagrisso (osimertinib) / AstraZeneca |
NCT02179671: Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer |
|
|
| Completed | 2a | 32 | US | Gefitinib, AZD9291, Selumetinib+Docetaxel, Tremelimumab | AstraZeneca, Quintiles, Inc. | Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) | 06/16 | 06/16 | | |
|
|
| Completed | 2a | 22 | Europe | Osimertinib, AZD9291 | MedSIR, AstraZeneca | Non-Small Cell Lung Cancer | 12/18 | 02/20 | | |
CTR20212842: Phase II clinical study of the safety and efficacy of JMT101 combined with osimertinib in patients with stage IIIb-IV non-small cell lung cancer with EGFR mutations |
|
|
| Not yet recruiting | 2 | 296 | China | Tagrisso (osimertinib) - AstraZeneca | Shanghai Jinmante Biotechnology Co., Ltd. | EGFR mutated stage IIIb-IV non-small cell lung cancer | | | | |
OSIRAM-1, jRCT2080224085: A Randomized Phase II Study of Osimertinib + Ramucirumab Versus Osimertinib as First-Line Chemotherapy for EGFR Mutation-Positive Non-Squamous Cell Non-Small Cell Lung Cancer |
|
|
| Completed | 2 | 120 | Japan | Tagrisso (osimertinib) - AstraZeneca, Cyramza (ramucirumab) - Eli Lilly | Kanagawa Prefectural Cancer Center | EGFR mutation-positive non-squamous non-small-cell lung cancer | | | | |
YAMATO, jRCTs031200021: A Randomized Phase II Study of Switching Therapy from Afatinib to Osimertinib in the Initial Treatment of Epidermal Growth Factor Receptor (EGFR) Gene Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer (TORG1939/WJOG12919L) |
|
|
| Completed | 2 | 110 | Japan | Gilotrif (afatinib) - Boehringer Ingelheim | Kansai Medical University Hospital | Lung cancer | | | | |
TORG2040, jRCTs041200100: First-Line Osimertinib for Poor Performance Status Patients with EGFR Mutant Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 30 | Japan | Tagrisso (osimertinib) - AstraZeneca | Kitasato University Hospital | Non-small cell lung cancer | | | | |
ACTRN12623000552684: OCEANiC: A Phase II, Open-label, Multi-centre Clinical Trial of Osimertinib With or Without Adjuvant Chemotherapy Guided by Tumour NGS Co-mutation Status and ctDNA Detection in Patients With
Stage IIA-IIIA EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection |
|
|
| Recruiting | 2 | 100 | | | The University of Sydney, AstraZeneca Australia Pty Ltd | EGFR-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection | | | | |
| Completed | 2 | 210 | Europe, Canada, Japan, US, RoW | AZD9291 | AstraZeneca | Non Small Cell Lung Cancer | 05/15 | 11/23 | | |
EAY131-E, NCT06303167: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) |
|
|
| Active, not recruiting | 2 | 19 | NA | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Osimertinib, AZD 9291, AZD-9291, AZD9291, Mereletinib, Radiologic Examination, Radiologic Evaluation, Radiologic Exam | National Cancer Institute (NCI) | Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma | 02/23 | 12/25 | | |
2015-001970-16: this trial is finalized to evaluate the tolerability and the quality of life in patients with Lung cancer who take AZD9291 Questa sperimentazione ¿ finalizzata a valutare la tollerabilit¿ e l'impatto sulla qualit¿ della vita dei pazienti affetti da tumore polmonare che assumono AZD9291 |
|
|
| Ongoing | 2 | 32 | Europe | AZD9291, Capsule, hard | ASSOCIAZIONE PIEMONTESE DI ONCOLOGIA TORACICA (APOT), AstraZeneca | Subjects with EGFRm+/T790M, locally advanced or metastatic NSCLC who have progressed following prior therapy with an approved EGFR-TKI Pazienti con EGFRm+/T790M, affetti da NSCLC localmente avanzato o metastatico la cui malattia ¿ in progressione dopo precedente terapia con EGFR-TKI, lung cancer Patients progressed after a previous chemotherapy Pazienti affetti da tumore al polmone in progressione dopo una precedente terapia, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 171 | RoW | AZD9291 | AstraZeneca | Non-Small Cell Lung Cancer | 03/16 | 12/22 | | |
|
2014-000814-73: National Lung Matrix: Multi-drug Phase II trial in Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 620 | Europe | Palbociclib, Xalkori, Selumetinib, Docetaxel, Taxotere, Taxceus, Sitravatinib, AZD4547, AZD2014, PD 0332991, PF-02341066, AZD6244, ARRY 142886, MEDI4736, AZD5363, AZD9291, MGCD516, Tablet, Capsule, Concentrate for solution for infusion, Lyophilisate for solution for infusion, Xalkori, Docetaxel, Taxotere, Taxceus | University of Birmingham, AstraZeneca, Pfizer, Cancer Research UK | Metastatic or locally advanced non-small cell lung cancer (NSCLC), Commonest form of lung cancer, non-small cell lung cancer (NSCLC), Diseases [C] - Cancer [C04] | | | | |
2016-002555-17: Phase II Study evaluating the effect of osimertinib in patients with non-small cell lung cancer locally advanced or metastatic with T790M resistance mutation "not evaluable or unknown", undergoing chemotherapy after failure of treatment with tyrosine kinase inhibitors. Studio di fase II di valutazione dell'effetto di osimertinib in pazienti affetti da carcinoma polmonare non a piccole cellule localmente avanzato o metastatico con mutazione di resistenza T790M ¿non valutabile o non nota¿, sottoposti a chemioterapia dopo fallimento del trattamento con inibitori delle tirosinchinasi. |
|
|
| Not yet recruiting | 2 | 90 | Europe | osimertinib, AZD9291, Film-coated tablet, Tagrisso | AZIENDA OSPEDALIERO - UNIVERSITARIA "POLICLINICO - VITTORIO EMANUELE", AstraZeneca | Locally Advanced or Metastatic EGFR mutated, "T790M undetectable or unknown" Non Small Cell Lung Cancer (Stage IIIB-IV) Carcinoma polmonare non a piccole cellule localmente avanzato o metastatico (stadio IIIB-IV) EGFR mutato, con mutazione T790M ¿non valutabile o non nota¿, Locally Advanced or Metastatic Lung Cancer with undetectable or unknown tyrosin-kinase resistance mutation. Tumore al polmone localmente avanzato o metastatico con mutazione di resistenza agli inibitori delle tirosinchinasi non valutabile o non nota., Diseases [C] - Cancer [C04] | | | | |
2016-001834-82: Clinical trial to assess the feasibility and the activity of osimertinib on patients with non small cell lung cancer |
|
|
| Ongoing | 2 | 156 | Europe | osimertinib, gefitinib, AZD9291, ZD1839, Film-coated tablet, Tablet, Tagrisso, Iressa | European Organisation for Research and Treatment of Cancer (EORTC), EORTC, Astra Zeneca | NSCLC patients, Lung cancer called "non small cell lung cancer (NSCLC)", Diseases [C] - Cancer [C04] | | | | |
| Unknown status | 2 | 37 | RoW | AZD9291 | Samsung Medical Center | Non Small Cell Lung Cancer | 12/17 | 07/19 | | |
ABCD-study, UMIN000030545: Afatinib plus Bevacizumab Combination after osimertinib failure for aDvanced EGFR-mutant non-small cell lung cancer: a multicenter prospective single arm phase II study |
|
|
| Ongoing | 2 | 26 | Japan | Gilotrif (afatinib) - Boehringer Ingelheim, Avastin (bevacizumab) - Roche | Hanshin Oncology Group, Boehringer Ingelheim Japan | Advanced EGFR-mutant non-small cell lung cancer | | | | |
2018-001863-21: Novel treatment for people with lung cancer harbouring a specific mutation |
|
|
| Not yet recruiting | 2 | 120 | Europe | Tagrisso 40 mg film-coated tablet, Tagrisso 80 mg film-coated tablet, Tablet, Tagrisso | Vestre Viken Hospital Trust, Vestre Viken Hospital Trust | Lung Cancer, Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
LiquidLung-O, NCT02769286: Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA |
|
|
| Completed | 2 | 38 | RoW | Osimertinib, AZD9291 | Chonnam National University Hospital | Lung Neoplasms, EGFR Gene Mutations | 12/18 | 05/20 | | |
2018-003218-42: MEchanisms of resitance in EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtib Mécanismes de résistance chez des patients avec un cancer du poumon avancé non prétraité, EGFR muté, recevant un traitement par OSIMERTINIB |
|
|
| Not yet recruiting | 2 | 66 | Europe | osimertinib, Film-coated tablet, Tagrisso 40mg, Tagrisso 80mg | CHU de Nantes, AstraZeneca | Locally advanced or metastatic Non-small-cell lung carcinoma Cancer du poumon non à petites cellules localement avancé ou métastatique, Non-small-cell lung carcinoma Cancer du poumon non à petites cellules, Diseases [C] - Cancer [C04] | | | | |
2017-004734-28: Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial. |
|
|
| Not yet recruiting | 2 | 15 | Europe | osimertinib, AZD9291, Tablet, Tagrisso | University Medical Center Groningen, University Medical Center Groningen | Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial., Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial., Diseases [C] - Cancer [C04] | | | | |
NCT02811354: Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA |
|
|
| Unknown status | 2 | 108 | RoW | AZD9291, Osimertinib | National University Hospital, Singapore, AstraZeneca, Singapore Clinical Research Institute | Carcinoma, Non-Small-Cell Lung | 02/19 | 02/20 | | |
2018-003012-51: Osimertinib plus savolitinib in patients with EGFRm+/MET+ non small cell lung cancer following prior osimertinib |
|
|
| Not yet recruiting | 2 | 360 | Europe | osimertinib 80 mg, osimertinib 40 mg, Savolitinib, AZD9291, AZD6094, Film-coated tablet, Coated tablet, TAGRISSO | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
ACTRN12617000720314: Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer |
|
|
| Completed | 2 | 50 | | | University of Sydney, AstraZeneca | EGFR-T790M mutation positive advanced non-small cell lung cancer | | | | |
ChiCTR1800016544: A Open-label, Double arms, pilot Phase II study in single centre to Evaluate the Efficacy of early conversion to Osimertinib Versus continue to First-generation EGFR-TKIs in patients with acquired T790M mutation positive in EGFR-mutant NSCLC patients after Treating with First-generation EGFR-TKIs |
|
|
| Not yet recruiting | 2 | 100 | | Osimertinib ;First-generation EGFR-TKIs/Osimertinib | Hangzhou Cancer Hospital; Hangzhou Cancer Hospital, Shuwen Biotech Co. Ltd | Non-Small Cell Lung Cancer | | | | |
NCT03257124: Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS |
|
|
| Active, not recruiting | 2 | 80 | RoW | AZD9291, Osimertinib | Samsung Medical Center | Non-Small Cell Lung Cancer With EGFR T790M Mutation, With Brain and/or Leptomeningeal Metastasis, Failed Tyrosine Kinase Inhibitors | 08/19 | 12/21 | | |
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig |
|
|
| Not yet recruiting | 2 | 30 | Europe | Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo | Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark | Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04] | | | | |
2019-001538-33: This study will look at whether the study drug Tepotinib works to stop the re-growth of your lung cancer. The study drug will be used in combination with an approved lung cancer medication called osimertinib, which is an EGFR inhibitor. This is a Phase II study, which means that the study drug has already been tested in a small number of people in previous clinical research studies. Only patient who have progressed on first-line osimertinib due to MET amplification will be enrolled in the study |
|
|
| Not yet recruiting | 2 | 122 | Europe | tepotinib, MSC2156119J, Film-coated tablet, TAGRISSO | Merck Healthcare KGaA, MERCK HEALTHCARE KGaA, Merck Healthcare KGaA | Locally advanced or metastatic NSCLC histology (confirmed by either histology or cytology) with documented activating mutation of the EGFR receptor including T790M statusResistance on previous first line osimertinib, Lung Cancer, Diseases [C] - Cancer [C04] | | | | |
2019-002805-23: Study of osimertinib in patients with a lung cancer with Brain or Leptomeningeal metastases with harboring a EGFR mutation |
|
|
| Not yet recruiting | 2 | 112 | Europe | Osimertinib, AZD9291, Film-coated tablet, Tagrisso | IFCT, IFCT, AstraZeneca | EGFR-mutated Non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases, lung cancer with Brain or Leptomeningeal metastases with harboring a EGFR mutation, Diseases [C] - Cancer [C04] | | | | |
ALTN-03, NCT04029350: Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M |
|
|
| Unknown status | 2 | 53 | RoW | Anlotinib Combined With Osimertinib, A+T | Tianjin Medical University Cancer Institute and Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/20 | 11/21 | | |
| Unknown status | 2 | 48 | Europe | AZD9291, Tagrisso, Osimertinib | Hellenic Oncology Research Group | Non Small Cell Lung Cancer | 06/20 | 12/20 | | |
OWBLM, NCT04425681: Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer |
|
|
| Unknown status | 2 | 20 | RoW | Osimertinib, Bevacizumab | Second Affiliated Hospital of Nanchang University, Nanchang University | Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation | 07/20 | 06/21 | | |
NCT04591002: Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) |
|
|
| Withdrawn | 2 | 56 | RoW | Osimertinib 80 MG | Samsung Medical Center | Lung Cancer | 10/20 | 10/20 | | |
NCT03460275: Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer |
|
|
| Unknown status | 2 | 100 | RoW | Osimertinib Mesylate Tablets | Sun Yat-sen University | Non-small Cell Lung Cancer | 12/20 | 12/20 | | |
OWONBNSCLCLM, NCT04148898: Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis |
|
|
| Unknown status | 2 | 80 | NA | Osimertinib, AZD9291, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb | Second Affiliated Hospital of Nanchang University, Nanchang University | Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation | 03/21 | 07/21 | | |
NCT03394118: TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy |
|
|
| Completed | 2 | 63 | RoW | Osimertinib | Asan Medical Center, AstraZeneca | NSCLC | 03/21 | 04/21 | | |
TRAEMOS, NCT03784599: T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC |
|
|
| Terminated | 2 | 28 | Europe | Trastuzumab emtansine, Osimertinib | The Netherlands Cancer Institute, AstraZeneca, Roche Pharma AG | Carcinoma, Non-Small-Cell Lung | 05/21 | 05/21 | | |
ChiCTR1800019710: Osimertinib combined with Pemetrexed compared to Osimertinib monotherapy in the treatment of patients EGFR T790M–Positive Lung Cancer: a prospective, phase II randomized controlled trial |
|
|
| Not yet recruiting | 2 | 100 | | Pemetrexed | Fujian Tumor Hospital; Fujian Tumor hospital, Patients at his own expense | adenocarcinoma lung cancer | | | | |
NEOS, ChiCTR1800016948: A multicenter, open-label, single arm pilot study: Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma |
|
|
| Recruiting | 2 | 40 | | neoadjuvant osimertinib | Thoracic Surgery II, Beijing Cancer Hospital; China anti-cancer association, AstraZeneca Pharmaceutical Company | Lung cancer | | | | |
| Completed | 2 | 15 | RoW | Osimertinib 80 MG [Tagrisso] | Seoul National University Hospital, AstraZeneca, Korean Cancer Study Group | Locally Advanced or Metastatic NSCLC | 08/21 | 08/21 | | |
JMT101-CSP-005, NCT06391944: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations |
|
|
| Active, not recruiting | 2 | 161 | RoW | JMT101 Injection, Osimertinib tablet | Shanghai JMT-Bio Inc. | Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation | 05/23 | 11/26 | | |
2020-003512-27: Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study |
|
|
| Not yet recruiting | 2 | 60 | Europe | Osimertinib, Film-coated tablet, Osimertinib | AIO-Studien-gGmbH, AstraZeneca GmbH | Patients with EGFR-mutation positive NSCLCThe target population will comprise 3 parallel cohorts, for each of which a minimum of 10 subjects is planned to be enrolled:1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases2. Irradiation of brain metastases (initial lesion size < 3 cm)3. Irradiation of lung lesions (primary tumor or metastases, lesion size < 5 cm), Patients with non-small lung cancer patients will be classified in 3 cohorts; Irradiation of 1. bone, solid organ or soft-tissue metastases2. brain metastases 3. lung lesions, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 16 | Europe | Osimertinib | University Hospital, Essen | NSCLC, EGFR T790M, FDG-PET | 12/21 | 09/22 | | |
PCA, NCT04136535: Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC |
|
|
| Unknown status | 2 | 105 | RoW | Pemetrexed, Carboplatin, Anlotinib | Fudan University | NSCLC Stage IV | 12/21 | 12/21 | | |
2020-004114-35: A clinical study exploring the effect of osimertinib and radiation therapy, in people with newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene. Un estudio clínico que explora el efecto del osimertinib y la radioterapia en personas con cáncer de pulmón de células no pequeñas (CPCNP) recién diagnosticado que se ha diseminado a algunas otras partes del cuerpo y muestra un cambio (mutación) en el gen EGFR. |
|
|
| Not yet recruiting | 2 | 60 | Europe | Osimertinib, [AZD9291], Tablet, Tagrisso | European Thoracic Oncology Platform (ETOP), EUROPEAN THORACIC ONCOLOGY PLATFORM, ETOP IBCSG Partners Foundation, AstraZeneca AG Switzerland | Treatment naïve patients with synchronous, oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC with or without T790M resistance mutation Pacientes sin tratamiento previo con NSCLC sincrónico, oligo-metastásico (tumor primario y un máximo de 5 metástasis) mutante EGFR (deleción del exón 19 o exón 21 L858R) con o sin mutación de resistencia T790M, newly diagnosed non-small cell lung cancer (NSCLC) that has spread to a few other parts of the body and shows a change (mutation) in the EGFR gene. Cáncer de pulmón de células no pequeñas (CPCNP) recién diagnosticado que se ha diseminado a algunas otras partes del cuerpo y muestra un cambio (mutación) en el gen EGFR., Diseases [C] - Cancer [C04] | | | | |
2021-003305-21: First-line Osimertinib plus Consolidation Radiotherapy compared with Osimertinib alone in oligometastatic NSCLC EGFR mutated patients: the randomized phase II OCRa trial GOIRC-06-2019 Studio randomizzato di fase II di confronto tra Osimertinib in associazione alla radioterapia di consolidamento e Osimertinib da solo in pazienti con tumore polmonare non a piccole cellule (NSCLC) in stadio oligometastatico e con mutazione a carico di EGFR: studio OCRa- GOIRC-06-2019 |
|
|
| Not yet recruiting | 2 | 80 | Europe | TAGRISSO 80 mg, TAGRISSO 40 mg, [TAGRISSO 80 mg], [TAGRISSO 40 mg], Tablet, TAGRISSO | GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), AstraZeneca S.p.A. | EGFR mutated NSCLC patients with oligometastatic disease pazienti con NSCLC EGFR mutati e in stadio oligometastatico, patients NonSmal Cell Lung Cancer, EGFR mutated oligometastatic disease pazienti con carcinoma polmonare non a piccole cellule EGFR mutati e in stadio oligometastatico, Diseases [C] - Cancer [C04] | | | | |
NCT04316351: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Recruiting | 2 | 60 | RoW | Toripalimab + Pemetrexed + Anlotinib, JS001 | Guangzhou Institute of Respiratory Disease, Shanghai Junshi Bioscience Co., Ltd. | IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy | 04/22 | 04/22 | | |
NCT02759835: Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib |
|
|
| Completed | 2 | 37 | US | osimertinib, Tagrisso, Local Ablative Therapy (LAT) | National Cancer Institute (NCI) | Lung Adenocarcinoma, Lung Neoplasms | 05/22 | 09/22 | | |
NCT05458726: Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC |
|
|
| Recruiting | 2 | 80 | RoW | Osimertinib, paclitaxel, carboplatin, pemetrexed | Peking Union Medical College | EGFR T790M, Osimertinib, Non-small Cell Lung Cancer, ddPCR | 07/22 | 10/22 | | |
INDIGO, NCT04644432: Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | Europe | Medication (A specification is listed under each arm), Patient reported outcomes measurement, PRO | Herlev and Gentofte Hospital | Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms | 09/22 | 09/22 | | |
ChiCTR2000036856: Treatment strategy of malignant pleural effusion in EGFR sensitive mutant lung cancer: a prospective, randomized controlled trial |
|
|
| Not yet recruiting | 2 | 200 | | Osimertinib alone ;Osimertinib combined with pleurodesis | Shanghai Chest hospital; Shanghai Chest hospital, Three year action plan for promoting clinical skills and clinical innovation in municipal hospitals (2020-2022) major clinical research projects | lung cancer | | | | |
| Completed | 2 | 17 | US | osimertinib, Tagrisso | Duke University | Non Small Cell Lung Cancer | 10/22 | 10/22 | | |
NCT04517526: Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study |
|
|
| Not yet recruiting | 2 | 60 | RoW | pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT | Shanghai Cancer Hospital, China | Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT | 11/22 | 12/22 | | |
NCT04099836: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib |
|
|
| Terminated | 2 | 7 | US | Atezolizumab, TECENTRI, Bevacizumab, Avastin | Duke University | Non Small Cell Lung Cancer | 11/22 | 06/23 | | |
NCT02824952: Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC |
|
|
| Recruiting | 2 | 40 | RoW | Tagrisso, AZD9291 | Shaare Zedek Medical Center, AstraZeneca | Lung Cancer, Non-small Cell | 12/22 | 12/22 | | |
| Terminated | 2 | 3 | RoW | osimertinib mesylate tablets and anlotinib hydrochloride capsules, TAGRISSO and FOCUS V | First Affiliated Hospital of Zhejiang University | Non Small Cell Lung Cancer | 12/22 | 02/23 | | |
CoC, NCT04606771: A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC |
|
|
| Active, not recruiting | 2 | 30 | US, RoW | Osimertinib + Savolitinib, Savolitinib + Placebo | AstraZeneca | Non-Small Cell Lung Cancer | 12/22 | 12/24 | | |
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation |
|
|
| Recruiting | 2 | 6000 | RoW | Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc. | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation | 12/26 | 12/27 | | |
NCT02736513: Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases |
|
|
| Active, not recruiting | 2 | 40 | RoW | AZD9291, TAGRISSO | Soroka University Medical Center | Lung Cancer | 12/22 | 12/22 | | |
NCT03433469: Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery |
|
|
| Active, not recruiting | 2 | 27 | US | Osimertinib, AZD-9291, Tagrisso, Therapeutic Conventional Surgery | University of California, San Francisco, AstraZeneca | Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer | 01/23 | 10/26 | | |
| Active, not recruiting | 2 | 156 | Europe, RoW | Osimertinib, AZD9291, Tagrisso, Gefitinib, Iressa | European Organisation for Research and Treatment of Cancer - EORTC, AstraZeneca | NSCLC | 02/23 | 12/27 | | |
2021-002337-42: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed with advanced non-small cell lung cancer (NSCLC) that shows a change (mutation) in the EGFR gene and has spread to other parts of the body during or after treatment with osimertinib or lazertinib. Un estudio clínico que explora el efecto del tratamiento con amivantamab y lazertinib más bevacizumab, en personas diagnosticadas con cáncer de pulmón de células no pequeñas (CPCNP) avanzado que muestra un cambio (mutación) en el gen EGFR y se ha diseminado a otras partes del cuerpo durante o después del tratamiento con osimertinib o lazertinib. |
|
|
| Ongoing | 2 | 60 | Europe | Amivantamab, Lazertinib, Concentrate for solution for infusion, Film-coated tablet, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceutica | patients with EGFR-mutant advanced NSCLC with progression on previous third generation EGFR TKI Pacientes con NSCLC avanzado con mutación de EGFR con progresión en TKI de EGFR de tercera generación anterior, Patients with non-small cell lung cancer that:• Has a change (mutation) in a gene called EGFR• Has spread to other parts of the body during, or after treatment with osimertinib or lazertinib. Pacientes con cáncer de pulmón de células no pequeñas:• Con mutación en un gen llamado EGFR• Se ha propagado a otras partes del cuerpo durante/ después del tratamiento con osimertinib o lazertinib, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 2 | 648 | Europe, Canada, US, RoW | Poziotinib | Spectrum Pharmaceuticals, Inc | NSCLC | 04/23 | 04/23 | | |
|
|
|
|
|
|
|
|
| Terminated | 2 | 5 | RoW | osimertinib, AZD9291, Tagrisso | AstraZeneca | Lung Cancer | 03/23 | 03/23 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
| Active, not recruiting | 2 | 155 | Europe, RoW | Osimertinib, Tagrisso, Bevacizumab, Avastin | ETOP IBCSG Partners Foundation, AstraZeneca, Hoffmann-La Roche | Non Small Cell Lung Cancer Metastatic | 05/23 | 05/23 | | |
|
| Active, not recruiting | 2 | 140 | Europe, Japan, US, RoW | Tepotinib, Osimertinib, Tagrisso® | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Non-small Cell Lung Cancer | 05/23 | 10/25 | | |
TREM, NCT02504346 / 2015-000307-10: AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies |
|
|
| Active, not recruiting | 2 | 200 | Europe | AZD9291 | Oslo University Hospital, AstraZeneca | Lung Cancer, Targeted Therapy | 06/23 | 06/23 | | |
ChiCTR2300070023: Osimertinib plus Anlotinib as first-line treatment for coexisting EGFR mutation advanced NSCLC: a single-arm, open-label, phase II study |
|
|
| Recruiting | 2 | 35 | | Osimertinib Plus Anlotinib | Dongguan People’s Hospital; Dongguan People’s Hospital, Medical research development fund project of Beijing kangmeng Charity Foundation | Non-small cell Lung Cancer | | | | |
NCT05477615: Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases |
|
|
| Not yet recruiting | 2 | 28 | RoW | Lazertinib, YH25448, Pemetrexed, Carboplatin | Jin Hyoung Kang, Korea University Anam Hospital | Non-small Cell Lung Cancer | 06/23 | 06/25 | | |
WJOG9717L, UMIN000030206: Randomized phase II study of osimertinib plus bevacizumab and osimertinib for chemotherapy-naive patients with nonsquamous non-small cell lung cancer harboring EGFR mutations (investigator-initiated multicenter clinical trial, ) |
|
|
| Completed | 2 | 122 | Japan | Tagrisso (osimertinib) - AstraZeneca, Avastin (bevacizumab) - Roche | Shizuoka Cancer Center, AstraZeneca K.K. | NSCLC | | | | |
OUTRUN, NCT03497767: A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases |
|
|
| Completed | 2 | 40 | RoW | Osimertinib, Tagrisso, Stereotactic Radiosurgery (SRS) | Trans Tasman Radiation Oncology Group | Metastatic Non Small Cell Lung Cancer | 04/24 | 04/24 | | |
NCT05507606: Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations |
|
|
| Recruiting | 2 | 50 | RoW | Osimertinib, EGFR-TKI, Bevacizumab Biosimilar IBI305, Anti-angiogenesis, Carboplatin, Chemotherapy, Pemetrexed | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer | 08/23 | 08/24 | | |
ChiCTR2100049904: Clinical observation of continuous treatment with almonertinib after treatment with osimertinib in EGFR mutation positive advanced NSCLC patients with drug resistance |
|
|
| Not yet recruiting | 2 | 30 | | Almonertinib 110 mg orally,once a day | Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University; Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Huilan charity-Hansoh pharma | Lung Cancer | | | | |
FIOL, NCT03804580: First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 100 | Europe | osimertinib | Vestre Viken Hospital Trust | Lung Cancer | 06/25 | 12/25 | | |
NCT02664935: National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 423 | Europe | AZD4547, Vistusertib, AZD2014, Palbociclib, Crizotinib, Selumetinib, AZD6244, Docetaxel, AZD5363, Osimertinib, AZD9291, Durvalumab, MEDI4736, Sitravatinib, MGCD516, AZD6738 | University of Birmingham, Cancer Research UK, AstraZeneca, Pfizer, Experimental Cancer Medicine Centres, Mirati Therapeutics Inc. | Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma | 09/24 | 09/24 | | |
|
|
| Recruiting | 2 | 30 | RoW | Osimertinib, AZD9291, TAGRISSO, Cisplatin, DDP, Pemetrexed | Sun Yat-sen University | Non-Small Cell Lung Cancer | 09/23 | 09/28 | | |
| Completed | 2 | 154 | Europe, US, RoW | Osimertinib, TAGRISSO, AZD9291 | AstraZeneca, Parexel | EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 09/23 | 09/23 | | |
BECOME, NCT05132777: Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 155 | NA | JMT101, Osimertinib Mesylate Tablets | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 09/23 | 09/24 | | |
RAMOSE, NCT03909334: Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 160 | US | Osimertinib, Tagrisso, Ramucirumab, Cyramza | Xiuning Le, M.D. Anderson Cancer Center, Eli Lilly and Company | Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer | 09/25 | 10/25 | | |
BLOSSOM, NCT04563871: Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) |
|
|
| Completed | 2 | 73 | RoW | 80mg Osimertinib, Tagrisso 80mg | Samsung Medical Center, AstraZeneca | Non-small Cell Lung Cancer (NSCLC) | 10/23 | 10/23 | | |
NCI-2018-02010, NCT03732352: 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma |
|
|
| Active, not recruiting | 2 | 12 | US | Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Osimertinib, AZD-9291, AZD9291, Mereletinib, Tagrisso, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging | Jonsson Comprehensive Cancer Center, AstraZeneca | EGFR Gene Amplification, EGFR Gene Mutation, Glioblastoma, Recurrent Glioblastoma, Supratentorial Glioblastoma, TP53 wt Allele | 10/24 | 10/25 | | |
| Recruiting | 2 | 50 | Europe | Osimertinib, Tagrisso, Pemetrexed, Cisplatin, Carboplatin | Goethe University | NSCLC Stage IIIB, NSCLC Stage IV | 11/23 | 11/26 | | |
NCT04545710: Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance |
|
|
| Active, not recruiting | 2 | 18 | US | Abemaciclib, Verzenios, Osimertinib, Tagrisso | University of California, San Diego, Eli Lilly and Company | Lung Cancer | 12/25 | 12/26 | | |
NCT04519983: Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs |
|
|
| Recruiting | 2 | 40 | RoW | Aumolertinib Oral Tablet, Stereotactic Radiation Therapy | Shanghai Cancer Hospital, China | Lung Cancer Stage IV | 12/23 | 12/23 | | |
| Active, not recruiting | 2 | 44 | RoW | Osimertinib, AZD9291, Savolitinib, HMPL-504 | Guangdong Association of Clinical Trials | Carcinoma, Non-Small-Cell Lung | 04/24 | 08/26 | | |
NCT06142617: A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. |
|
|
| Not yet recruiting | 2 | 37 | RoW | Pembrolizumab, pemetrexed, platinum, Keytruda, pemetrexed, platinum, Osimertinib | Peking Union Medical College Hospital | Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation | 11/27 | 06/28 | | |
| Recruiting | 2 | 170 | Europe | Osimertinib, Tagrisso, Dacomitinib, Vizimpro | Fondazione Ricerca Traslazionale, Pfizer srl | NSCLC | 12/23 | 12/23 | | |
NCT04764214: SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs |
|
|
| Completed | 2 | 61 | RoW | 3rd generation EGFR-TKI, Osimertinib, Consolidative SRT | Fudan University | NSCLC Stage IV, EGFR Activating Mutation | 03/23 | 07/23 | | |
| Recruiting | 2 | 21 | Europe | Afatinib, Osimertinib, Carboplatin and Pemetrexed | VU University Medical Center, Boehringer Ingelheim | Non-Small Cell Lung Cancer | 01/24 | 01/25 | | |
NCT06206850: Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib |
|
|
| Not yet recruiting | 2 | 20 | NA | Osimertinib, Tagrisso | Jair Bar, M.D., Ph.D. | Non-squamous NSCLC | 01/29 | 01/30 | | |
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment |
|
|
| Not yet recruiting | 2 | 40 | NA | Almonertinib, HS-10296 | Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer, EGFR Gene Mutation | 01/24 | 01/24 | | |
NCT06185400: RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations |
|
|
| Not yet recruiting | 2 | 108 | NA | Disitamab Vedotin, RC48, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin | 07/25 | 12/26 | | |
NCT06296745: Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. |
|
|
| Not yet recruiting | 2 | 36 | NA | Pemetrexed | Guangzhou Medical University | Leptomeningeal Metastasis | 01/26 | 03/26 | | |
| Active, not recruiting | 2 | 41 | US | Osimertinib, AZD9291, TAGRISSO, SABR | University of Texas Southwestern Medical Center, AstraZeneca | Non-small Cell Lung Cancer (NSCLC) | 09/24 | 04/25 | | |
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib |
|
|
| Active, not recruiting | 2 | 150 | Europe | TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis | Nantes University Hospital, AstraZeneca | Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
NCT04829019: Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI |
|
|
| Recruiting | 2 | 88 | RoW | Osimertinib and whole-brain irradiation, Osimertinib | Sun Yat-sen University | Neurocognitive | 04/24 | 10/25 | | |
FLAME, NCT04769388: Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib |
|
|
| Recruiting | 2 | 150 | RoW | Osimertinib, AZD9291, Tagrisso, Pemetrexed/Carboplatin | Beijing Cancer Prevention & Treatment Society, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non Small Cell Lung Cancer | 04/24 | 09/24 | | |
NCT06319950: High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases |
|
|
| Not yet recruiting | 2 | 255 | NA | Furmonertinib, AST2818, alflutinib, Osimertinib, AZ9291 | Taizhou Hospital | Lung Cancer, Nonsmall Cell | 12/26 | 12/26 | | |
GALAXY-02, NCT06383728: Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 51 | RoW | Osimertinib, Tagrisso | The First Affiliated Hospital of Guangzhou Medical University | Lung Cancer, Carcinoma, Squamous Cell | 10/25 | 04/29 | | |
NCT06363734: Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial |
|
|
| Recruiting | 2 | 32 | RoW | Osimertinib plus Dalpiciclib | Tianjin Medical University Cancer Institute and Hospital | Non-small Cell Lung Cancer, EGFR Activating Mutation, Cell Cycle Deregulation, EGFR-TKI Resistant Mutation | 12/25 | 12/26 | | |
